EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

RAnoLazIne for the treatment of diastolic heart failure in patients with preserved ejection fraction: the RALI-DHF proof-of-concept study



RAnoLazIne for the treatment of diastolic heart failure in patients with preserved ejection fraction: the RALI-DHF proof-of-concept study



Jacc. Heart Failure 1(2): 115-122



This study investigated whether inhibiting late Na(+) current by using ranolazine improved diastolic function in patients with heart failure with preserved ejection fraction (HFpEF). HFpEF accounts for >50% of all HF patients, but no specific treatment exists. The RALI-DHF (RAnoLazIne for the Treatment of Diastolic Heart Failure) study was a prospective, randomized, double-blind, placebo-controlled small proof-of-concept study. Inclusion criteria were EF ≥45%, a mitral E-wave velocity/mitral annular velocity ratio (E/E') >15 or N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration >220 pg/ml, a left ventricular end-diastolic pressure (LVEDP) ≥18 mm Hg, and time-constant of relaxation (tau) ≥50 ms. Patients were randomized to ranolazine (n = 12) or placebo (n = 8). Treatment consisted of intravenous infusion for 24 h, followed by oral treatment for 13 days. After 30 min of infusion, LVEDP (p = 0.04) and pulmonary capillary wedge pressure (p = 0.04) decreased in the ranolazine group but not in the placebo group. Mean pulmonary artery pressure showed a trend toward a decrease in the ranolazine group that was significant under pacing conditions at 120 beats/min (p = 0.02), but not for the placebo group. These changes occurred without changes in left ventricular end-systolic pressure or systemic or pulmonary resistance but in the presence of a small but significant decrease in cardiac output (p = 0.04). Relaxation parameters (e.g., tau, rate of decline of left ventricular pressure per minute [dP/dtmin]) were unaltered. Echocardiographically, the E/E' ratio did not significantly change after 22 h. After 14 days of treatment, no significant changes were observed in echocardiographic or cardiopulmonary exercise test parameters. There were no significant effects on NT-pro-BNP levels. Results of this proof-of-concept study revealed that ranolazine improved measures of hemodynamics but that there was no improvement in relaxation parameters. (Ranolazine in Diastolic Heart Failure [RALI-DHF]; NCT01163734).

(PDF emailed within 0-6 h: $19.90)

Accession: 055333532

Download citation: RISBibTeXText

PMID: 24621836

DOI: 10.1016/j.jchf.2012.12.002



Related references

Ranolazine for the treatment of heart failure with preserved ejection fraction: background, aims, and design of the RALI-DHF study. Clinical Cardiology 34(7): 426-432, 2011

Ranolazine for the treatment of pulmonary hypertension associated with heart failure with preserved ejection fraction: A pilot study. Journal of Heart and Lung Transplantation 35(11): 1370-1373, 2016

Effects of exercise on left ventricular systolic and diastolic properties in patients with heart failure and a preserved ejection fraction versus heart failure and a reduced ejection fraction. Circulation. Heart Failure 6(3): 508-516, 2013

Ranolazine prevents heart failure with preserved ejection fraction, diastolic dysfunction, and left ventricular hypertrophy in a hypertensive murine model. Cardiovascular Revascularization Medicine 13(2): 147-0, 2012

Long-term administration of ranolazine attenuates diastolic dysfunction and adverse myocardial remodeling in a model of heart failure with preserved ejection fraction. International Journal of Cardiology 217(): 69-79, 2016

Exercise training in heart failure with preserved ejection fraction: beyond proof-of-concept. Journal of the American College of Cardiology 58(17): 1792-1794, 2011

Heart failure with normal ejection fraction, heart failure with preserved ejection fraction, diastolic heart failure, or huff-puff: time for a new taxonomy for hypertensive-metabolic heart failure. Journal of Cardiac Failure 20(10): 779-781, 2015

Microvascular Paradigm in Heart Failure With Preserved Ejection Fraction: A Quest for Proof of Concept. Circulation. Heart Failure 10(6): -, 2017

Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation 121(12): 1393-1405, 2010

D-ribose aids heart failure patients with preserved ejection fraction and diastolic dysfunction: a pilot study. Therapeutic Advances in Cardiovascular Disease 9(3): 56-65, 2016

Diastolic stress test echocardiography in patients with suspected heart failure with preserved ejection fraction: a pilot study. Esc Heart Failure 6(1): 146-153, 2018

Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction). Circulation 135(8): 724-735, 2017

Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circulation. Heart Failure 4(3): 324-331, 2011

Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction Study. Circulation. Heart Failure 9(1): -, 2016

Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. American Heart Journal 162(6): 966-972.E10, 2012